Literature DB >> 3856510

Quantitation of anthracyclines in human hematopoietic cell subpopulations by flow cytometry correlated with high pressure liquid chromatography.

P A Speth, P C Linssen, J B Boezeman, H M Wessels, C Haanen.   

Abstract

The major white cell subpopulations present in bone marrow and peripheral blood can be discriminated by forward and perpendicular light scatter two-parameter flow cytometry (FCM). Fluorescent properties of anthracycline antibiotics allow measurement of the concentration of these cytotoxic drugs in hematopoietic cells by FCM as a third parameter. Analysis of scatter-gated fluorescence histograms provides quantitative information about the cellular concentration of at least four cell categories in human blood and bone marrow cells. A good correlation was found between the mean cellular fluorescence measured by FCM and the overall cellular concentration of adriamycin, daunomycin, and their main metabolites determined with high-pressure liquid chromatography (HPLC). In incubation experiments with human hematopoietic tissues, the final concentration of various anthracyclines in subpopulations of white cells appeared to be dependent on cell density, incubation time, temperature, and type of compound and its concentration. FCM analysis is a rapid, sensitive, and quantitative method for measurement of cellular anthracycline concentrations in subpopulations and therefore provides an useful new tool in monitoring chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3856510     DOI: 10.1002/cyto.990060210

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  10 in total

1.  Cell cycle kinetics of hematopoiesis before and after in vivo administration of GM-CSF in refractory anemia: evidence for a shortening of the granulocyte release time.

Authors:  P P Brons; N Van der Lely; C Haanen; A H Pennings; J B Boezeman; J M Wessels; R A Raijmakers; T J de Witte
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

2.  Quantitation of cell-associated doxorubicin by high-performance liquid chromatography after enzymatic desequestration.

Authors:  A Andersen; D J Warren; L Slørdal
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

Review 4.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

5.  Cellular and plasma pharmacokinetics of weekly 20-mg 4'-epi-adriamycin bolus injection in patients with advanced breast carcinoma.

Authors:  P A Speth; P C Linssen; L V Beex; J B Boezeman; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type.

Authors:  A Reichle; H Diddens; F Altmayr; J Rastetter; R Andreesen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM).

Authors:  R Raijmakers; P Speth; T de Witte; P Linssen; J Wessels; C Haanen
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

10.  Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention.

Authors:  R Supino; E Prosperi; F Formelli; M Mariani; G Parmiani
Journal:  Br J Cancer       Date:  1986-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.